These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 17287624

  • 1. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.
    Young G, Yonekawa KE, Nakagawa PA, Blain RC, Lovejoy AE, Nugent DJ.
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):97-103. PubMed ID: 17287624
    [Abstract] [Full Text] [Related]

  • 2. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography.
    Young G, Yonekawa KE, Nakagawa PA, Blain RC, Lovejoy AE, Nugent DJ.
    Blood Coagul Fibrinolysis; 2007 Sep; 18(6):547-53. PubMed ID: 17762530
    [Abstract] [Full Text] [Related]

  • 3. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
    Nielsen VG, Steenwyk BL, Gurley WQ, Pereira SJ, Lell WA, Kirklin JK.
    J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
    [Abstract] [Full Text] [Related]

  • 4. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing.
    Gosselin RC, King JH, Janatpur KA, Dager WH, Larkin EC, Owings JT.
    Arch Pathol Lab Med; 2004 Oct; 128(10):1142-5. PubMed ID: 15387708
    [Abstract] [Full Text] [Related]

  • 5. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin.
    Tanaka KA, Szlam F, Sun HY, Taketomi T, Levy JH.
    Anesth Analg; 2007 Oct; 105(4):933-9, table of contents. PubMed ID: 17898368
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile.
    Gerotziafas GT, Chakroun T, Samama MM, Elalamy I.
    Thromb Haemost; 2004 Dec; 92(6):1296-302. PubMed ID: 15583737
    [Abstract] [Full Text] [Related]

  • 8. Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant.
    Olah Z, Szarvas M, Bereczky Z, Kerenyi A, Kappelmayer J, Boda Z.
    Arch Pathol Lab Med; 2013 Jul; 137(7):967-73. PubMed ID: 23808469
    [Abstract] [Full Text] [Related]

  • 9. Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro.
    Xu Y, Wu W, Wang L, Chintala M, Plump AS, Ogletree ML, Chen Z.
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):332-8. PubMed ID: 23348428
    [Abstract] [Full Text] [Related]

  • 10. Effect of heparin and Bivalirudin on the kinetics of clot formation: Viscoelastic coagulation testing.
    Hasija S, Kapoor PM.
    Ann Card Anaesth; 2017 Apr; 20(1):122. PubMed ID: 28074815
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
    Lind SE, Boyle ME, Fisher S, Ishimoto J, Trujillo TC, Kiser TH.
    Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
    [Abstract] [Full Text] [Related]

  • 12. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE, Greinacher A, Craven S, Dewar L, Sheppard JA, Ofosu FA.
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [Abstract] [Full Text] [Related]

  • 13. Hydroxyethyl starch enhances argatroban-mediated decreases in clot propagation and strength by diminishing thrombin-fibrinogen interactions.
    Nielsen VG, Kirklin JK.
    Blood Coagul Fibrinolysis; 2007 Jan; 18(1):49-54. PubMed ID: 17179827
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII.
    Nielsen VG, Kirklin JK.
    Blood Coagul Fibrinolysis; 2008 Dec; 19(8):793-800. PubMed ID: 19002046
    [Abstract] [Full Text] [Related]

  • 18. Thrombin-directed inhibitors: pharmacology and clinical use.
    White CM.
    Am Heart J; 2005 Jan; 149(1 Suppl):S54-60. PubMed ID: 15644794
    [No Abstract] [Full Text] [Related]

  • 19. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.
    Berry CN, Girardot C, Lecoffre C, Lunven C.
    Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788
    [Abstract] [Full Text] [Related]

  • 20. Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa.
    Siddiqui F, Tafur A, Bontekoe E, Iqbal O, Jeske W, Mehrotra S, Hoppensteadt D, Ramacciotti E, Fareed J.
    Clin Appl Thromb Hemost; 2020 Sep; 26():1076029619895120. PubMed ID: 31914798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.